Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business News In Brief

Executive Summary

Novartis runs counter to sales call trends for first half of 2010: With a strong emphasis on detailing newly launched hypertension drug Valturna (aliskiren/valsartan), Novartis saw its volume of sales calls to doctors, nurses and physician assistants increase 7 percent during the first half of 2010, in contrast to industry trends. In a newly issued report, health care market analytics firm SDI announced overall sales calls by pharma companies to clinicians decreased 1 percent during the first six months of the year, compared to the second half of 2009. Based on SDI's findings, Merck sales calls declined 16 percent and GlaxoSmithKline's 7 percent. The industry's biggest company, Pfizer, posted a 2 percent decrease in sales calls during the half-year. At Novartis, a full 19 percent of sales calls were used to discuss Valturna, a combination drug approved by FDA last September that comprises the active ingredients in Diovan and Tekturna (1Pharmaceutical Approvals Monthly, October 2009). With pharmaceutical sales forces being reduced in recent years, the drop in sales calls may be slowing, SDI Associate Director of Syndicated Analytics Jason Fox said, but in-person calls remain the most popular method of informing clinicians of new drugs, second only to product sampling

You may also be interested in...



Business News, In Brief

Cephalon's Buchi steps in for Baldino: Cephalon CEO Frank Baldino is taking a temporary medical leave of absence, and the company's long-time financial head Kevin Buchi will take over his responsibilities in the meantime, the firm announced Aug. 25. Buchi, having worked with Baldino for decades, is well-groomed to step in. He joined Cephalon in 1991 as controller and was appointed CFO in 1996. He was promoted to Chief Operating Officer earlier this year. Baldino is due to return to the company before the end of the year. If his absence is indeed only a few months long, the disruption should not have a material impact on the company, given Cephalon's experienced leadership team. A longer-term absence, however, could raise some investor alarms, because Baldino, who founded Cephalon in 1987, is the face of the company and has been steering the ship from the get-go

Business News, In Brief

Cephalon's Buchi steps in for Baldino: Cephalon CEO Frank Baldino is taking a temporary medical leave of absence, and the company's long-time financial head Kevin Buchi will take over his responsibilities in the meantime, the firm announced Aug. 25. Buchi, having worked with Baldino for decades, is well-groomed to step in. He joined Cephalon in 1991 as controller and was appointed CFO in 1996. He was promoted to Chief Operating Officer earlier this year. Baldino is due to return to the company before the end of the year. If his absence is indeed only a few months long, the disruption should not have a material impact on the company, given Cephalon's experienced leadership team. A longer-term absence, however, could raise some investor alarms, because Baldino, who founded Cephalon in 1987, is the face of the company and has been steering the ship from the get-go

Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition

HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law

Related Content

Topics

UsernamePublicRestriction

Register

PS052536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel